Clinical trials: Solid Tumors, completed
Solid Tumor, Cutaneous Squamous Cell Carcinoma
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
The purpose of this study is to evaluate pathologic complete response (pCR) rate of coformulated favezelimab/pembrolizumab (MK-4280A) or pembrolizumab as assessed by blinded central pathology review (BICR) in participants with…
- Conditions
- Solid Tumor, Cutaneous Squamous Cell Carcinoma, Endometrial Cancer
- Trial name
- NCT06036836
- Testing
- favezelimab/pembrolizumab, pembrolizumab, lenvatinib
- Where
- 44 sites in United States, Australia and 8 more
- Volunteers
- 163 people
- Sponsor
- Merck Sharp & Dohme LLC
Solid Tumor, Adult
Study of DF1001 in Patients With Advanced Solid Tumors
DF1001-001 is a study of a new molecule that targets natural killer (NK) cells and T-cell activation signals to specific receptors on cancer cells. The study will occur in two phases.
- Trial name
- NCT04143711
- Testing
- DF1001, Nivolumab, Nab paclitaxel
- Where
- 44 sites in United States, Belgium and 4 more
- Volunteers
- 270 people
- Sponsor
- Dragonfly Therapeutics
Solid Tumor
A Study of Azenosertib (ZN-c3) in Participants With Solid Tumors
This is a Phase 1 open-label, multicenter study of ZN-c3 (also known as Azenosertib) monotherapy which consists of Dose Escalation, a Food Effect Cohort, and Dose Expansion.
- Trial name
- NCT04158336
- Testing
- Azenosertib
- Where
- 8 sites in United States
- Volunteers
- 274 people
- Sponsor
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Solid Tumors
A Study of DF6002 Alone and in Combination With Nivolumab
The purpose of this study is to evaluate the safety, tolerability, drug-levels, drug-effects and preliminary anti-tumor activity of DF6002 alone and in combination with Nivolumab in participants with advanced solid tumors.
- Trial name
- NCT04423029
- Testing
- DF6002, Nivolumab
- Where
- 32 sites in United States, Australia and 2 more
- Volunteers
- 170 people
- Sponsor
- Dragonfly Therapeutics
Solid Tumor, Adult, Solid Tumor Cancer
Study of DF6215 in Patients With Advanced Solid Tumors
A Phase I/Ib, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF6215 Monotherapy and in Combination Therapy in Patients with Advanced…
- Trial name
- NCT06108479
- Testing
- DF6215, pembrolizumab, KEYTRUDA®
- Where
- 21 sites in United States, Australia and 1 more
- Volunteers
- 35 people
- Sponsor
- Dragonfly Therapeutics
Solid Tumor, KRAS Mutation
A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus
This study is no longer open to new participants. It was a study in adults with advanced cancer in the stomach and oesophagus. This is a study for people for whom previous treatment was not successful or no treatment exists.
- Trial name
- NCT06056024
- Testing
- BI 3706674
- Where
- 17 sites in United States, Japan and 2 more
- Volunteers
- 47 people
- Sponsor
- Boehringer Ingelheim
Cancer, Solid Tumor
Prevalence of Creatinine Phosphokinase Increase in Patients With Solid Tumors Treated by Inhibitors of Tyrosine Kinases
This study describes the elevation of CPK in patient treated for solid tumors by TKI
- Trial name
- TKI-CPK (NCT01248429)
- Testing
- CPK dosage, Clinical exam
- Where
- 27 sites in France
- Volunteers
- 154 people
- Sponsor
- Centre Oscar Lambret
Solid Tumor
Screening for Vulnerability in the Elderly Supported at the Oscar Lambret Centre
The objective of this study is to uncover the prevalence of vulnerability among patients aged ≥ 70 coming to the medical oncology division of the Oscar Lambret Centre, according to the short screening test Vulnerable Elders…
- Trial name
- VULNERABILITE (NCT01415258)
- Where
- France
- Volunteers
- 209 people
- Sponsor
- Centre Oscar Lambret
Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8
ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors
This phase Ib trial studies the side effects and best dose of ALRN-6924 when given together with paclitaxel in treating patients with solid tumors that have spread to other places in the body or cannot be removed by surgery.
- Conditions
- Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8
- Trial name
- NCT03725436
- Testing
- MDM2/MDMX Inhibitor ALRN-6924, Paclitaxel
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumors
Phase Ia/Ib Study of RS-0139 in Patients With a Recurrent, Locally Advanced or Metastatic Solid Tumors
This study designed as a multicenter, open label, two-step study to determine the optimum dose, pharmacokinetics, and the safety of RS-0139 in patients with a recurrent, locally advanced or metastatic solid tumors.
- Trial name
- NCT04261413
- Testing
- RS-0139
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 16 people
- Sponsor
- RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S.
Solid Tumor
A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors
This is a Phase 1 dose-escalation and expansion study that will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of SAIL66 in patients with CLDN6-positive locally advanced…
- Trial name
- NCT05735366
- Testing
- SAIL66
- Where
- 9 sites in United States, Japan
- Volunteers
- 22 people
- Sponsor
- Chugai Pharmaceutical
Any Advanced Solid Tumors, Triple Negative Breast Cancer
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
The main purposes of Phase 1b of this study are to determine the following in participants with advanced solid tumors: Safety and tolerability of NT-I7 in combination with pembrolizumab Maximum Tolerated Dose (MTD) and/or the…
- Conditions
- Any Advanced Solid Tumors, Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT04332653
- Testing
- NT-I7, pembrolizumab (KEYTRUDA®)
- Where
- 8 sites in United States
- Volunteers
- 215 people
- Sponsor
- NeoImmuneTech
Solid Tumors With Oligometastatic Spread
5 Fraction Stereotactic Body Radiation Therapy for Oligometastases Regimen, for Extra-Cranial Oligometastases
This is a prospective Phase II study.The purpose of this study is to monitor the side effects and treatment outcomes of delivering higher doses of radiation therapy to the tumour, while limiting the dose of radiation to the…
- Trial name
- 5fr SBRT (NCT01761929)
- Testing
- Radiation: 50Gy in 5 fr (max) to 25 Gy in 5 fr (min). Dose adapted to deliver the highest dose level while respecting normal tissue tolerance
- Where
- Canada
- Volunteers
- 138 people
- Sponsor
- University Health Network, Toronto
Solid Tumor
TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 Monotherapy
This is an open-label, phase 1, dose-escalation, multicenter trial evaluating the safety of oncolytic adenovirus TILT-123 as monotherapy in advanced solid tumor patients.
- Trial name
- TUNIMO (NCT04695327)
- Testing
- TILT-123
- Where
- 2 sites in Finland
- Volunteers
- 32 people
- Sponsor
- TILT Biotherapeutics Ltd.
Advanced Solid Tumor, Advanced Colorectal Carcinoma
Combining Epigenetic And Immune Therapy to Beat Cancer.
Umbrella study structure to independently and simultaneously assess the effects of the association of durvalumab and tazemetostat in multiple solid tumors.
- Conditions
- Advanced Solid Tumor, Advanced Colorectal Carcinoma, Advanced Soft-tissue Sarcoma, Advanced Pancreatic Adenocarcinoma
- Trial name
- CAIRE (NCT04705818)
- Testing
- Durvalumab, Tazemetostat
- Where
- 3 sites in France
- Volunteers
- 164 people
- Sponsor
- Institut Bergonié
Non Small Cell Lung Cancer, Advanced Solid Tumor
Implementing Circulating Tumor DNA Analysis at Initial Diagnosis to Improve Management of Advanced NSCLC Patients
Multicenter prospective cohort study aiming to evaluate the detection rate of EGFR gene mutation in patients with advanced NSCLC in a real-word clinical setting, based on liquid biopsy and tissue analyses.
- Trial name
- CIRCULAR (NCT04912687)
- Testing
- EGFR gene mutation analysis on liquid biopsy
- Where
- 9 sites in France
- Volunteers
- 581 people
- Sponsor
- Institut Bergonié
Tumor, Solid
Varian ProBeam Proton Therapy System Clinical Trial (Shandong)
This study is prospective, single-center, single-arm objective performance criteria. This trial will be conducted with a total of 47 subjects enrolled.
- Trial name
- NCT06340815
- Testing
- Radiation: Proton Therapy System (ProBeam)
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Varian, a Siemens Healthineers Company
Solid Tumors With PTCH1 Loss-of-function Mutations
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
This study employs a 2-stage design that aims to evaluate the efficacy and safety of ENV- 101, a potent Hedgehog (Hh) pathway inhibitor, in patients with refractory advanced solid tumors characterized by loss of function (LOF)…
- Trial name
- NCT05199584
- Testing
- ENV-101 (taladegib)
- Where
- 16 sites in United States
- Volunteers
- 20 people
- Sponsor
- Endeavor Biomedicines, Inc.
Advanced Solid Tumours
Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours
This study will assess the safety, tolerability, and pharmacokinetics of AZD1775 (adavosertib) given orally in combination with intravenous MEDI4736 (durvalumab).
- Trial name
- NCT02617277
- Testing
- AZD1775, MEDI4736
- Where
- 3 sites in United States
- Volunteers
- 56 people
- Sponsor
- AstraZeneca
Hematopoietic Neoplasm, Malignant Solid Neoplasm
Addressing Financial Hardship in Adolescent and Young Adult Cancer Survivors
This study seeks to develop, test, and revise an intervention designed to address financial hardship (FinFit) among adolescent and young adult (AYA) cancer survivors.
- Conditions
- Hematopoietic Neoplasm, Malignant Solid Neoplasm, Lymphatic System Neoplasm
- Trial name
- FinFit Aim 1 (NCT06881108)
- Testing
- CHAT Core Functions, LIFT Core Functions, Member-Checking Process
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Wake Forest University Health Sciences